=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=O/S/N
VAR G2=O/S/N/C
VPA 22-1/2/3 U
VPA 23-12/13/14 U
NODE ATTRIBUTES:
NSPEC IS R AT 20
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8 4
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 11:33:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9947 TO ITERATE

100.0% PROCESSED 9947 ITERATIONS 1702 ANSWERS
SEARCH TIME: 00.00.01

L3 1702 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	176.60	176.81

FILE 'CAPLUS' ENTERED AT 11:33:33 ON 22 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 20 Feb 2007 (20070220/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 27 L3

=> d bib abs 1-26

L4 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1173484 CAPLUS
DN 145:489283
TI N-Acylpiperidines and related compounds as CGRP-antagonists, methods for preparing them, pharmaceutical compositions and their use as pharmaceutical compositions
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 156pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006252931	A1	20061109	US 2006-277177	20060322
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	AR 2005-101139	A	20050323		
	WO 2005-EP3094	A	20050323		
	WO 2005-EP4104	A	20050418		
	EP 2005-21283	A	20050929		
	DE 2004-102004015723	A	20040329		
	DE 2004-102004019492	A	20040422		

OS MARPAT 145:489283
GI



I



II

AB The invention relates to the CGRP-antagonists of general formula I, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixts. and salts thereof and the hydrates of the salts, particularly the physiol. acceptable salts thereof with inorg. or organic acids or bases, as well as those compds. of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compns. containing these compds., the use thereof and processes for the preparation thereof. Compds. of formula I wherein X is CH2, NH, C1-3 alkyl-N, O and S; R1 is (spiro)substituted piperidine and oxodihydrothienopyrimidinyl; R2 is (un)substituted (un)fused aryl, and (un)substituted (un)fused pyridine; R3 is (un)substituted piperidine, (un)substituted piperazine, and (un)substituted diazepine; R4 is (un)substituted 4- to 7-membered oxycycloalkyl; and their tautomers and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by cyclization of 2-amino-3-methylphenol with CDI; the resulting 4-methyl-3H-benzoxazole-2-one underwent bromination to give 6-bromo-4-methyl-3H-benzoxazol-2-one, which underwent coupling with Me 2-acetylaminoacrylate to give Me 2-acetylamino-3-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)acrylate, which underwent hydrolysis to give 3-(4-methyl-2-oxo-2,3-dihydrobenzoxazole-6-yl)-2-oxopropionic acid, which underwent asym. reduction to give (R)-2-hydroxy-3-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)propionic acid, which underwent esterification to give the corresponding Me ester, which reacted with 4-nitrophenyl chloroformate and 3-(piperidin-4-yl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one followed by hydrolysis to give (R)-1-carboxy-2-(4-methyl-2-oxo-2,3-dihydrobenzoxazol-6-yl)ethyl 4-(2-oxo-1,3,4,5-tetrahydro-1,3-benzodiazepin-3-yl)piperidine-1-carboxylate, which underwent amidation with 1-(tetrahydropyran-4-yl)piperazine to give compound II. All the invention compds. were evaluated for their CGRP binding affinity. The tested compds. exhibited IC50 values ≥ 10 000 nM.

L4 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1005390 CAPLUS
DN 145:356814
TI Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines and related compounds as CGRP receptor antagonists

IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Doods, Henri; Arndt, Kirsten; Schaenzle, Gerhard

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 231pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	WO 2005-EP3094	A	20050323		
	WO 2005-EP4104	A	20050418		
	EP 2005-21283	A	20050929		
	DE 2004-102004015723	A	20040329		
	DE 2004-102004019492	A	20040422		

OS MARPAT 145:356814

GI



I

II

AB Title compds. I [X = CH2, NH, O, etc.; R1 = substituted 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines, etc.; R2 = 5-methylquinoxalines, 8-methylimidazo[1,2-a]pyridines, etc.; R3 = substituted piperidines, piperazines, etc.; R4 = 4 to 7-membered ocicycloalkyl ring with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, benzodiazepinylpiperidine II was prepared from 5-amino-m-cresol in 8-steps. In CGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1005389 CAPLUS
DN 145:377393
TI Preparation of 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines as CGRP receptor antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 183pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006100026	A1	20060928	WO 2006-EP2557	20060321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRAI WO 2005-EP3094 A 20050323
DE 2004-102004015723 A 20040329

OS MARPAT 145:377393

GI



I



II

AB Title compds. I [B = substituted Ph, phenols, anilines, etc.; Y = C, N; R3 = cyclopentyl, cyclohexyl, cycloheptyl; R4 = H with provisos] and their pharmaceutically acceptable salts were prepared For example, benzodiazepinylpiperidine II was prepared from 3-trifluoromethylbenzaldehyde in 7-steps. In CGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:656692 CAPLUS
DN 145:96491
TI Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Schaenzle, Gerhard; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2006069754	A1	20060706	WO 2005-EP13974	20051223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	DE 102004063755	A1	20060720	DE 2004-102004063755	20041229
	US 2006154921	A1	20060713	US 2005-301422	20051213
PRAI	DE 2004-102004063755	A	20041229		

AB The invention discloses a method for treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a selected CGRP antagonist to the patient, as well as the use of the active compds. for the manufacture of a pharmaceutical composition intended to be used in this method.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:636811 CAPLUS
DN 145:76714
TI Use of selected CGRP antagonists for combating menopausal hot flushes
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schaenzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PI	US 2006142274	A1	20060629	US 2005-301446	20051213
	DE 102004063752	A1	20060713	DE 2004-102004063752	20041229
	WO 2006072415	A1	20060713	WO 2005-EP13972	20051223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	DE 2004-102004063752	A	20041229		

AB The invention discloses the use of selected CGRP antagonists, the physiol. acceptable salts thereof or the hydrates or the hydrates of the salts thereof for combating menopausal hot flushes. A variety of formations are included.

L4 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:636805 CAPLUS
DN 145:96481
TI Use of selected CGRP antagonists in combination with other antimigraine drugs for the treatment of migraine
IN Rudolf, Klaus; Doods, Henri; Mueller, Stephan Georg; Zamponi, Annette; Lustenberger, Philipp; Arndt, Kirsten; Schaenzle, Gerhard; Stenkamp, Dirk; Brickl, Rolf-Stefan
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006142273	A1	20060629	US 2005-275169	20051216
DE 102004063753	A1	20060713	DE 2004-102004063753	20041229
WO 2006072413	A1	20060713	WO 2005-EP13964	20051223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI DE 2004-102004063753 A 20041229
AB The invention discloses a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, the process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiol. acceptable salt thereof or a hydrate of the salt and a therapeutically effective amount of a second or third active anti-migraine medicament (B), particularly sumatriptan, zolmitriptan, or dihydroergotamine, or a physiol. acceptable salt thereof, as well as the corresponding pharmaceutical compns. and the preparation thereof. A variety of formulations are included.

L4 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:315123 CAPLUS
DN 144:460321
TI Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead
AU Williams, Theresa M.; Stump, Craig A.; Nguyen, Diem N.; Quigley, Amy G.; Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blair; Wan, Bang-Lin; Della Penna, Kimberly; Kunapuli, Priya; Kane, Stefanie A.; Koblan, Ken S.; Mosser, Scott D.; Rutledge, Ruth Z.; Salvatore, Christopher; Fay, John F.; Vacca, Joseph P.; Graham, Samuel L.
CS Department of Medicinal Chemistry, Merck & Co., West Point, PA, 19486, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2595-2598
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:460321
AB High-throughput screening of the Merck sample collection identified a

benzodiazepinone tetralin-spirohydantoin as a CGRP receptor antagonist with micromolar activity. Comparing the structure of this compound with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinazolinone, CGRP receptor Ki = 44 nM and IC50 = 38 nM. This compound was orally bioavailabile in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:55281 CAPLUS
DN 144:205969
TI Identification and Pharmacological Characterization of Domains Involved in Binding of CGRP Receptor Antagonists to the Calcitonin-like Receptor
AU Salvatore, Christopher A.; Mallee, John J.; Bell, Ian M.; Zartman, C. Blair; Williams, Theresa M.; Koblan, Kenneth S.; Kane, Stefanie A.
CS Pain Research Medicinal Chemistry, and Biomedical Research Departments, Merck Research Laboratories, West Point, PA, 19486, USA
SO Biochemistry (2006), 45(6), 1881-1887
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
AB The calcitonin-like receptor (CLR) and the calcitonin receptor (CTR) interact with receptor activity-modifying protein 1 (RAMP1) at the cell surface to form heterodimeric receptor complexes. CLR and CTR are members of the class II (family B) G-protein-coupled receptors (GPCR) and bind calcitonin gene-related peptide (CGRP) with similar affinities when coexpressed with RAMP1. The observation that various nonpeptide CGRP receptor antagonists display a higher affinity for the CLR/RAMP1 complex than for CTR/RAMP1 provided an opportunity to investigate the mol. determinants of the differential receptor affinities of these antagonists. A chimeric receptor approach was utilized to identify key domains within CLR responsible for conferring high-affinity antagonist binding. Initial chimera expts. implicated distinct regions within CLR as responsible for the affinities of structurally diverse CGRP receptor antagonists. Dissection of these key regions implicated amino acids 37-63 located in the N-terminus of CLR as responsible for the high-affinity interaction of one structural class, while transmembrane domain (TM) 7 was responsible for the interaction of a second class of antagonist. A unique binding interaction in the N-terminus of CLR is consistent with the observation that these compds. also interact with the extracellular region of RAMP1 and could suggest the formation of a binding pocket between the two proteins. Conversely, a compound which interacted with TM7 did not display a similar RAMP1 dependence, suggesting an allosteric mechanism of antagonism. Collectively, these data provide insight into two alternative mechanisms of antagonism for this unique heterodimeric receptor complex.

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1170370 CAPLUS
DN 143:440449
TI Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzdiazepin-2-ones and related compounds as cgrp antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Santagostino, Marco; Paleari, Fabio; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim

Pharma Gmbh & Co. KG
SO PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005103037	A2	20051103	WO 2005-EP4104	20050418
	WO 2005103037	A3	20060112		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004019492	A1	20051110	DE 2004-102004019492	20040422
	CA 2565219	A1	20051103	CA 2005-2565219	20050418
	EP 1740577	A2	20070110	EP 2005-735460	20050418
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	US 2005256099	A1	20051117	US 2005-109968	20050420
	WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006252931	A1	20061109	US 2006-277177	20060322
PRAI	DE 2004-102004019492	A	20040422		
	DE 2004-102004015723	A	20040329		
	US 2004-569533P	P	20040510		
	AR 2005-101139	A	20050323		
	WO 2005-EP3094	A	20050323		
	WO 2005-EP4104	W	20050418		
	EP 2005-21283	A	20050929		

OS MARPAT 143:440449
GI



I



II

AB Title compds. I [A = O, S; X = O, S; Q = C or N-atom of a heterocyclic ring with provisos; R1 = 5 to 7-membered heterocycle, etc.; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, HCl mediated deprotection of Boc-isoindazole II (Z = Boc) afforded benzdiazepin-2-one II (Z = H) in 72% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

L4 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1154551 CAPLUS
DN 143:422350
TI Preparation of 1,3-dihydro-3-(4-piperidinyl)-2H-imidazo[4,5-c]quinolin-2-ones and related compounds as cgrp antagonists
IN Rudolf, Klaus; Mueller, Stephan Georg; Lustenberger, Philipp; Stenkamp, Dirk; Schaenzle, Gerhard; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005100352	A1	20051027	WO 2005-EP3759	20050409
	WO 2005100352	A8	20060105		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	DE 102004018796	A1	20051103	DE 2004-102004018796	20040415
	CA 2563386	A1	20051027	CA 2005-2563386	20050409
	EP 1737860	A1	20070103	EP 2005-729383	20050409
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	US 2005250763	A1	20051110	US 2005-107052	20050415
PRAI	DE 2004-102004018796	A	20040415		
	US 2004-569948P	P	20040511		
	WO 2005-EP3759	W	20050409		

OS MARPAT 143:422350
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF3, NH2, Cl, etc.; X = O, CH2, NH; R1 = 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-onyl, 1,3-dihydro-2H-benzimidazol-2-one, etc.; NR2R3 = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 1,4'-bipiperidine and acid II afforded imidazo[4,5-c]quinolin-2-one III in 76% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1152762 CAPLUS
DN 143:440448
TI Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzdiazepin-2-ones and related compounds as CGRP antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 102004018795	A1	20051027	DE 2004-102004018795	20040415
	CA 2562526	A1	20051027	CA 2005-2562526	20050409
	WO 2005100343	A1	20051027	WO 2005-EP3741	20050409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1737842	A1	20070103	EP 2005-731650	20050409
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				

	US 2005282857	A1	20051222	US 2005-107195	20050415
PRAI	DE 2004-102004018795	A	20040415		
	US 2004-570005P	P	20040511		
	WO 2005-EP3741	W	20050409		

OS MARPAT 143:440448
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF3, NH2, Cl, etc.; X = O, CH2, NH; R1 = 3,4-dihydro-2(1H)-quinazolinonyl, 1,3,4,5-tetrahydro-2H-benzo-1,3-diazepin-2-onyl; NR2R3 = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 4-(2-piperidin-1-yl-ethyl)piperidine and acid II afforded benzdiazepin-2-one III in 64% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

L4 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1132894 CAPLUS
DN 143:379858
TI CGRP antagonist in combination with a serotonin reuptake inhibitor for the treatment of migraine or other headache
IN Doods, Henri; Rudolf, Klaus
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005233980	A1	20051020	US 2005-108985	20050419
	DE 102004019736	A1	20051117	DE 2004-102004019736	20040420
	DE 102004063754	A1	20060713	DE 2004-102004063754	20041229
	CA 2563687	A1	20051103	CA 2005-2563687	20050418
	WO 2005102322	A1	20051103	WO 2005-EP4076	20050418
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1740175	A1	20070110	EP 2005-735425	20050418
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
PRAI	DE 2004-102004019736	A	20040420		
	US 2004-570379P	P	20040512		
	DE 2004-102004063754	A	20041229		
	WO 2005-EP4076	W	20050418		

AB The invention discloses a process for the treatment or prevention of headaches, migraine or cluster headache, comprising the joint administration of a therapeutically effective amount of a CGRP-antagonist

[e.g. 1-(N2-(3,5-dibromo-N-((4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl)-D-tyrosyl)-L-lysyl)-4-(4-pyridinyl)piperazine], or a physiol. acceptable salt thereof, and a therapeutically effective amount of the selective serotonin reuptake inhibitor [e.g. (+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine], or a physiol. acceptable salt thereof, as well as the corresponding pharmaceutical compns. and the preparation thereof.

L4 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1075789 CAPLUS
DN 143:367334
TI Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzdiazepin-2-ones as OCGRP receptor antagonists
IN Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Dreyer, Alexander; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard; Santagostino, Marco; Paleari, Fabio
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 318 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092880	A1	20051006	WO 2005-EP3094	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004015723	A1	20051020	DE 2004-102004015723	20040329
	AU 2005225539	A1	20051006	AU 2005-225539	20050323
	CA 2558889	A1	20051006	CA 2005-2558889	20050323
	EP 1732917	A1	20061220	EP 2005-741783	20050323
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	US 2005234067	A1	20051020	US 2005-93834	20050329
	WO 2006100009	A1	20060928	WO 2006-EP2515	20060318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	WO 2006100026	A1	20060928	WO 2006-EP2557	20060321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

	US 2006252750	A1	20061109	US 2006-277175	20060322
	US 2006252931	A1	20061109	US 2006-277177	20060322
	NO 2006004166	A	20061025	NO 2006-4166	20060914
PRAI	DE 2004-102004015723	A	20040329		
	US 2004-566394P	P	20040429		
	AR 2005-101139	A	20050323		
	WO 2005-EP3094	W	20050323		
	WO 2005-EP4104	A	20050418		
	EP 2005-21283	A	20050929		

OS MARPAT 143:367334
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds: I [A = O, S; X = O, S; D, E = CH, N with provisos; G = CRa; M = CRb; Q = CRc; Ra, Rb, Rc = H, halo, alkyl, etc.; R1 = 5 to 7-membered heterocycle; R2 = H, Ph, pyridinyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 1-(1-methylpiperidin-4-yl)piperazine and carboxylic acid II afforded benzdiazepine III in 87% yield. In human OCGRP receptor inhibition assays, compds. I exhibited IC50 values ≤ 10000 nM.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:232614 CAPLUS
DN 142:291385
TI Use of telmisartan and other agents for the prevention of migraine or other vascular headache
IN Davidai, Giora
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023250	A1	20050317	WO 2004-EP9709	20040901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2005065094	A1	20050324	US 2004-925788	20040824
	CA 2537748	A1	20050317	CA 2004-2537748	20040901
	EP 1663208	A1	20060607	EP 2004-764674	20040901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 2006234946	A1	20061019	US 2006-454720	20060616
PRAI	US 2003-500817P	P	20030905		
	US 2004-925788	A1	20040824		
	WO 2004-EP9709	W	20040901		

AB The invention discloses a method for the prophylaxis of vascular headaches which do not originate from hypertension, especially migraine, the method comprising administration of telmisartan to a subject in need of such a treatment. The invention also discloses a method for the prophylaxis of vascular headaches, comprising the co-administration of telmisartan in combination with other drugs, e.g. triptans, suitable for migraine prophylaxis and/or acute treatment of migraine.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:122798 CAPLUS
DN 142:212404
TI Use of CGRP antagonists or CGRP release inhibitor in treatment and prevention of hot flushes in prostate cancer patients
IN Doods, Henri; Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Hammar, Mats; Spetz, Anna-Clara
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 17 pp., which
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005032783	A1	20050210	US 2004-881892	20040630
	CA 2531407	A1	20050120	CA 2004-2531407	20040702
	WO 2005004869	A1	20050120	WO 2004-EP7228	20040702
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1648466	A1	20060426	EP 2004-763078	20040702
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-15335	A	20030707		
	US 2003-491576P	P	20030731		
	EP 2003-21802	A	20030926		
	US 2003-515817P	P	20031030		
	WO 2004-EP7228	W	20040702		

AB The invention relates to a method of treatment or prevention of hot flushes in men who underwent castration, e.g. due to androgen ablation treatment in prostate cancer therapy, comprising administration of an effective amount of a CGRP antagonist and/or of a CGRP release inhibitor to the patient, and to the use of said active compds. for the manufacture of a pharmaceutical composition intended to be used in this method.

L4 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:587914 CAPLUS
DN 141:140319
TI Preparation of amino acid dipiperidides as CGRP antagonists
IN Bauer, Eckhart; Gerlach, Kai; Hurnaus, Rudolf; Mueller, Stephan; Rudolf, Klaus; Schindler, Marcus; Stenkamp, Dirk
PA Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
SO Ger. Offen., 98 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10300973	A1	20040722	DE 2003-10300973	20030114
	AU 2004203916	A1	20040729	AU 2004-203916	20040109
	CA 2513132	A1	20040729	CA 2004-2513132	20040109
	WO 2004063171	A1	20040729	WO 2004-EP87	20040109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA				
	EP 1587795	A1	20051026	EP 2004-700987	20040109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006762	A	20051220	BR 2004-6762	20040109
	CN 1738805	A	20060222	CN 2004-80002209	20040109
	JP 2006515875	T	20060608	JP 2006-500537	20040109
	US 2004192729	A1	20040930	US 2004-755593	20040112
	NO 2005003794	A	20050810	NO 2005-3794	20050810
PRAI	DE 2003-10300973	A	20030114		
	US 2003-443492P	P	20030129		
	WO 2004-EP87	W	20040109		

OS MARPAT 141:140319
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted diaza-, triaza-, S,S-dioxidothiadiaza-heterocycle; Ar = (un)substituted aryl, heteroaryl; Y = CH2, NH; Y1 = (un)substituted CH, N; R1 = (un)substituted N heterocycle; R2, R3 = H, carboxylic ester] were prepared for use as CGRP antagonists in the production and purification of antibodies and as marked compds. in RIA and ELISA assays and as diagnostic or analytic additives in neurotransmitter research (no data). Thus, the piperidide II was prepared from the amino acid and piperidine fragments in a multi-step synthesis.

L4 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:370923 CAPLUS
DN 140:391302
TI Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches
IN Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Arndt, Kirsten; Doods, Henri
PA Boehringer Ingelheim, Germany
SO PCT Int. Appl., 254 pp.
CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037811	A1	20040506	WO 2003-EP11763	20031023
	WO 2004037811	A8	20050519		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10250082	A1	20040513	DE 2002-10250082	20021025
	US 2004132716	A1	20040708	US 2003-685921	20031015
	CA 2503462	A1	20040506	CA 2003-2503462	20031023
	AU 2003276157	A1	20040513	AU 2003-276157	20031023
	EP 1558601	A1	20050803	EP 2003-809318	20031023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015642	A	20050830	BR 2003-15642	20031023
	CN 1708492	A	20051214	CN 2003-80101980	20031023
	JP 2006505573	T	20060216	JP 2004-545964	20031023
	ZA 2005002247	A	20050919	ZA 2005-2247	20050317
	NO 2005002493	A	20050524	NO 2005-2493	20050524
PRAI	DE 2002-10250082	A	20021025		
	US 2002-426167P	P	20021114		
	WO 2003-EP11763	W	20031023		

OS MARPAT 140:391302
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; Y, Z = alkyl, difluoromethyl, trifluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, benzo-1,3-diazepin-2-one II was prepared from 1-(3,4-diethylphenyl)ethanone in 8-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:370922 CAPLUS
DN 140:391301
TI Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches
IN Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Kirsten, Arndt; Doods, Henri
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO PCT Int. Appl., 315 pp.

CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037810	A1	20040506	WO 2003-EP11762	20031023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10250080	A1	20040513	DE 2002-10250080	20021025
	US 2006079504	A1	20060413	US 2003-687262	20031016
	CA 2503455	A1	20040506	CA 2003-2503455	20031023
	AU 2003276156	A1	20040513	AU 2003-276156	20031023
	EP 1558600	A1	20050803	EP 2003-809317	20031023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003015665	A	20050830	BR 2003-15665	20031023
	CN 1708493	A	20051214	CN 2003-80102004	20031023
	JP 2006516244	T	20060629	JP 2004-545963	20031023
	NO 2005002496	A	20050624	NO 2005-2496	20050524
PRAI	DE 2002-10250080	A	20021025		
	US 2002-426168P	P	20021114		
	WO 2003-EP11762	W	20031023		

OS MARPAT 140:391301
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; U = alkyl, alkenyl, alkynyl, etc.; V = Cl, Br, amino, etc.; W = H, halo, difluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, benzo-1,3-diazepin-2-one II was prepared from 4-amino-3-chloro-5-trifluoromethylbenzoic acid in 9-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:2675 CAPLUS
DN 140:65199
TI Preparations for the intranasal application of selected CGRP antagonists derived from amino acids and a method for their production
IN Kruss, Bernd; Gaiser, Marc A.; Busch, Ulrich; Jost, Klaus
PA Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent

LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000289	A2	20031231	WO 2003-EP6156	20030612
	WO 2004000289	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10227294	A1	20040108	DE 2002-10227294	20020619
	CA 2487716	A1	20031231	CA 2003-2487716	20030612
	AU 2003246414	A1	20040106	AU 2003-246414	20030612
	EP 1517674	A2	20050330	EP 2003-760605	20030612
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005530830	T	20051013	JP 2004-514694	20030612
	US 2004076587	A1	20040422	US 2003-463063	20030617
	US 2006193786	A1	20060831	US 2006-419218	20060519
PRAI	DE 2002-10227294	A	20020619		
	US 2002-395184P	P	20020711		
	WO 2003-EP6156	W	20030612		
	US 2003-463063	A1	20030617		

AB The invention relates to pharmaceutical compns. for nasal application, comprising selected CGRP antagonists, which are described in WO 98/11128, in addition to a method for their production Thus an aqueous solution with 10 % drug
and 1.75 mol-equivalent HCl contained: BIBN 4096 10 mg; 1N HCl 20.45 mg; mannitol 6 mg; water to 0.1 mL.

L4 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:12037 CAPLUS
DN 138:297955
TI Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist
AU Hasbak, Philip; Opgaard, Ole Saetrum; Eskesen, Karen; Schifter, Soren; Arendrup, Henrik; Longmore, Jenny; Edvinsson, Lars
CS Department of Clinical Experimental Research, University Hospital of Copenhagen, Glostrup, Den.
SO Journal of Pharmacology and Experimental Therapeutics (2003), 304(1), 326-333
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Calcitonin gene-related peptide (CGRP), adrenomedullin (AM), and amylin are structurally related peptides mediating vasorelaxation in the coronary circulation possibly via CGRP receptors (subtypes 1 or 2). Functional CGRP1 receptors appear to consist of at least three different kinds of proteins: the calcitonin receptor-like receptor (CRLR), receptor-activity-modifying proteins (RAMPs) and the receptor component protein (RCP). No CGRP2 receptor has yet been cloned. Using reverse transcriptase - polymerase chain reaction, the presence of mRNA sequences encoding CRLR, RCP and RAMPs was demonstrated in human coronary arteries. Relaxant responses were studied on isolated segments of coronary arteries after precontraction with U46619 (9,11-dideoxy-11α,9α-

epoxymethano-prostaglandin F2α). The human peptides αCGRP, AM, and amylin induced relaxation with mean pEC50 values of 8.6, 6.8, and 6.3 M, resp. Preincubation with αCGRP8-37 (10-7-10-5 M) and a novel nonpeptide CGRP antagonist "Compound 1" (WO98/11128) (10-7-10-5 M) caused a dose-dependent rightward shift of the concentration-response curves for αCGRP with pA2 values of 7.0 and 7.1, resp. Preincubation with αCGRP8-37 (10-6 M) and Compound 1 (10-6 M) caused significant rightward shift of the concentration-response curves for AM and amylin as well with pKB values between 6.6 and 7.5. Preincubation with AM22-52 had no antagonistic effect on the AM and amylin response, neither did diacetoamidomethyl cysteine CGRP cause any concentration dependent (10-11-10-6 M) dilatation. In conclusion, mRNA for the components forming CGRP1 and AM receptors was detected in the human left anterior descending coronary arteries. αCGRP, AM, and amylin mediated vasorelaxation via the CGRP1 receptor. Compound 1 acted as a nonpeptide antagonist at the CGRP1 receptor and could thus become a tool for the study of CGRP-mediated functional responses in human tissue.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:351484 CAPLUS
DN 137:304712
TI Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists
AU Mallee, John J.; Salvatore, Christopher A.; LeBourdelles, Beatrice; Oliver, Kevin R.; Longmore, Jenny; Koblan, Kenneth S.; Kane, Stefanie A.
CS Molecular Pharmacology Department, Merck Research Laboratories, West Point, PA, 19486, USA
SO Journal of Biological Chemistry (2002), 277(16), 14294-14298
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB The heterodimeric CGRP receptor requires co-expression of calcitonin receptor-like receptor (CRLR) and an accessory protein called receptor activity-modifying protein (RAMP) 1. Several non-peptide CGRP receptor antagonists have been shown to exhibit marked species selectivity, with > 100-fold higher affinities for the human CGRP receptor than for receptors from other species. This observation provided an opportunity to map the determinants of receptor affinity exhibited by BIBN4096BS and its truncated analogs. All three compds. exhibited higher affinity for the human receptor, human CRLR/human RAMP1, than for the rat receptor, rat CRLR/rat RAMP1. We have now demonstrated that this species selectivity was directed exclusively by RAMP1. By generating recombinant human/rat CRLR/RAMP1 receptors, we demonstrated that co-expression of human CRLR with rat RAMP1 produced rat receptor pharmacol., and vice versa. Moreover, with rat/human RAMP1 chimeras and site-directed mutants, we have identified a single amino acid at position 74 of RAMP1 that modulates the affinity of small mol. antagonists for CRLR/RAMP1. Replacement of lysine 74 in rat RAMP1 with tryptophan (the homologous amino acid in the human receptor) resulted in a ≥ 100-fold increase in antagonist affinities, similar to the Ki values for the human receptor. These observations suggest that important determinants of small mol. antagonist affinity for the CGRP receptor reside within the extracellular region of RAMP1 and provide evidence that this receptor accessory protein may participate in antagonist binding.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:656252 CAPLUS
DN 136:95802
TI CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with "Compound 1" (WO98/11128), a non-peptide antagonist
AU Hasbak, Philip; Sams, Anette; Schifter, Soren; Longmore, Jenny; Edvinsson, Lars
CS Department of Clinical Experimental Research, Department of Clinical Physiology and Nuclear Medicine, University Hospital of Glostrup, Glostrup, Den.
SO British Journal of Pharmacology (2001), 133(8), 1405-1413
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
AB 1 Calcitonin gene-related peptide (CGRP), amylin and adrenomedullin (AM) belong to the same family of peptides. Accumulating evidence indicate that the calcitonin (CT) receptor, the CT receptor-like receptor (CRLR) and receptor-activity-modifying proteins (RAMPs) form the basis of all the receptors in this family of peptides. 2 Using reverse transcriptase-polymerase chain reaction the presence of mRNA sequences encoding the CRLR, RAMP1 and RAMP2 were demonstrated in porcine left anterior descending (LAD) coronary arteries, whereas porcine calcitonin (CT) receptor mRNA was not present. The partial porcine mRNA sequences shared 82-92% nucleotide identity with human sequences. 3 The human peptides αCGRP, βCGRP, AM and amylin induced relaxation with pEC50 values of 8.1, 8.1, 6.7 and 6.1 M resp. 4 The antagonistic properties of a novel non-peptide CGRP antagonist "Compound 1" (WO98/11128), βCGRP8-37 and the proposed AM receptor antagonist AM22-52 were compared to the wellknown CGRP1 receptor antagonist αCGRP8-37. 5 The αCGRP8-37 and βCGRP8-37 induced concentration-dependent (10-7 - 10-5 M) rightward shift of both the αCGRP and βCGRP concentration-response curves. βCGRP8-37 (10-6 M) had the same effect as αCGRP8-37 (10-6 M), but with less potent rightward shift of the concentration-response curves for αCGRP, AM and amylin. 6 Preincubation with "Compound 1" (10-7 - 10-5 M) and AM22-52 (10-6 M) had no significant antagonistic effect. 7 In conclusion, the building blocks forming CGRP and AM receptors were present in the porcine LAD, whereas those of the amylin receptor were not, αCGRP, βCGRP, AM and amylin mediated vasorelaxation via the CGRP receptors. No functional response was detected to adrenomedullin via the adrenomedullin receptor.
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:164211 CAPLUS
DN 135:40865
TI Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries
AU Edvinsson, L.; Sams, A.; Jansen-Olesen, I.; Tajti, J.; Kane, S. A.; Rutledge, R. Z.; Koblan, K. S.; Hill, R. G.; Longmore, J.
CS Department of Internal Medicine, Lund University Hospital, Lund, S-22185, Swed.
SO European Journal of Pharmacology (2001), 415(1), 39-44
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
AB The cerebral circulation is innervated by calcitonin gene-related peptide (CGRP) containing fibers originating in the trigeminal ganglion. During a migraine attack, there is a release of CGRP in conjunction with the head pain, and triptan administration abolishes both the CGRP release and the

pain at the same time. In the search for a novel treatment of migraine, a non-peptide CGRP antagonist has long been sought. Here, we present data on a human cell line and human and guinea-pig isolated cranial arteries for such an antagonist, (4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)piperidine-1-carboxylic acid [1-(3,5-dibromo-4-hydroxy-benzyl)-2-oxo-2-(4-phenyl-piperazin-1-yl)ethyl]amide) (I). On SK-N-MC cell membranes, radiolabeled CGRP binding was displaced by both CGRP-(8-37) and I, yielding pKi values of 8.9 and 7.8, resp. Functional studies with SK-N-MC cells showed that CGRP-induced cAMP production was antagonized by both CGRP-(8-37) and I with pA2 values of 7.8 and 7.7, resp. Isolated human and guinea pig cerebral arteries were studied with a sensitive myograph technique. CGRP induced a concentration-dependent relaxation in human cerebral arteries which was antagonized by both CGRP-(8-37) and I in a competitive manner. In guinea pig basilar arteries, CGRP-(8-37) antagonized the CGRP-induced relaxation while I had a weak blocking effect. The clin. studies of non-peptide CGRP antagonists are awaited with great interest.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:114968 CAPLUS
DN 134:183478
TI Use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes
IN Doods, Henri; Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001010425	A2	20010215	WO 2000-EP7613	20000805
WO 2001010425	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19937304	A1	20010315	DE 1999-19937304	19990810
DE 19937304	C2	20030821		
US 6521609	B1	20030218	US 2000-614343	20000712
CA 2378428	A1	20010215	CA 2000-2378428	20000805
BR 2000013009	A	20020430	BR 2000-13009	20000805
TR 200200359	T2	20020521	TR 2002-359	20000805
EP 1207884	A2	20020529	EP 2000-958385	20000805
EP 1207884	B1	20041103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
ZA 2002000997	A	20020821	ZA 2002-997	20000805
HU 200202397	A2	20021028	HU 2002-2397	20000805
JP 2003506403	T	20030218	JP 2001-514945	20000805
EE 200200061	A	20030415	EE 2002-61	20000805
NZ 517367	A	20040924	NZ 2000-517367	20000805
AU 777709	B2	20041028	AU 2000-69928	20000805
AT 281168	T	20041115	AT 2000-958385	20000805
PT 1207884	T	20041231	PT 2000-958385	20000805

	ES 2231243	T3	20050516	ES 2000-958385	20000805
	IN 2002MN00130	A	20050318	IN 2002-MN130	20020130
	BG 106391	A	20020930	BG 2002-106391	20020206
	NO 2002000605	A	20020207	NO 2002-605	20020207
	HK 1046854	A1	20050225	HK 2002-108347	20021119
PRAI	DE 1999-19937304	A	19990810		
	US 2000-184800P	P	20000224		
	WO 2000-EP7613	W	20000805		

AB The invention relates to the use of CGRP antagonists and CGRP release inhibitors for controlling menopausal hot flashes. Thus, tablets contained a piperazine derivative containing D-tyrosine and D-lysine residues 20, lactose 120, corn starch 40, Mg stearate 2, and Povidone K-25 18 mg.

L4 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:643016 CAPLUS
DN 133:223053
TI Preparation of amino acid amide derivatives for use as calcitonin gene-related peptide antagonists in pharmaceutical compositions
IN Eberlein, Wolfgang; Rudolf, Klaus; Engel, Wolfhard; Doods, Henri; Hallermayer, Gerhard
PA Boehringer Ingelheim Pharma K.-G., Germany
SO Ger. Offen., 36 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19911039	A1	20000914	DE 1999-19911039	19990312
	CA 2361939	A1	20000921	CA 2000-2361939	20000308
	WO 2000055154	A1	20000921	WO 2000-EP2004	20000308
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1163239	A1	20011219	EP 2000-922505	20000308
	EP 1163239	B1	20030528		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539208	T	20021119	JP 2000-605583	20000308
	JP 3719937	B2	20051124		
	AT 241616	T	20030615	AT 2000-922505	20000308
	PT 1163239	T	20031031	PT 2000-922505	20000308
	ES 2199819	T3	20040301	ES 2000-922505	20000308
	US 6313097	B1	20011106	US 2000-523472	20000310
PRAI	DE 1999-19911039	A	19990312		
	US 1999-129937P	P	19990419		
	WO 2000-EP2004	W	20000308		

OS MARPAT 133:223053
GI



I

AB Title compds., e.g.(I; see patent for general claims), were prepared and tested as CGRP antagonists for use in pharmaceutical prepns. for treatment of headache, non-insulin dependent diabetes mellitus, cardiovascular diseases, skin diseases, inflammatory diseases, allergic rhinitis, asthma, morphine tolerance, and menopausal hot flashes (formulations given), and for use as diagnostic or anal. aides in RIA or ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research. Thus, di-Ph methanesulfonylimidocarbonate was reacted with 1-(4-amino-3,5-dibromo-D-phenylalanyl)-4-(1-piperidinyl)piperidine (as the bis-trifluoroacetate salt), and the product further reacted with 3,4-dihydro-3-(4-piperidinyl)-2(1H)-quinazolinone to give I (27%). In in vitro tests of human calcitonin gene related peptide (CGRP) receptor binding using Sk-N-MC-cells, title compds. had IC50 ≤ 104 nM, and in the same system, had CGRP-antagonist activity at doses from 10-11-10-5M.

L4 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:197358 CAPLUS
DN 128:257695
TI Preparation of modified amino acids and their use as calcitonin gene-related peptide antagonists in pharmaceutical compositions
IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Henri; Hallermayer, Gerhard; Entzeroth, Michael; Wienen, Wolfgang
PA Karl Thomae G.m.b.H., Germany
SO PCT Int. Appl., 461 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9811128	A1	19980319	WO 1997-EP4862	19970908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19636623	A1	19980312	DE 1996-19636623	19960910
DE 19720011	A1	19981119	DE 1997-19720011	19970514

	CA 2262818	A1	19980319	CA 1997-2262818	19970908
	AU 9741196	A	19980402	AU 1997-41196	19970908
	AU 721035	B2	20000622		
	EP 927192	A1	19990707	EP 1997-938928	19970908
	EP 927192	B1	20040512		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712023	A	19990831	BR 1997-12023	19970908
	JP 2000505100	T	20000425	JP 1998-513227	19970908
	JP 3483893	B2	20040106		
	HU 9904501	A2	20000428	HU 1999-4501	19970908
	AT 266673	T	20040515	AT 1997-938928	19970908
	EE 4375	B1	20041015	EE 1999-115	19970908
	PL 190180	B1	20051130	PL 1997-331989	19970908
	NO 9901130	A	19990505	NO 1999-1130	19990309
	KR 2000044040	A	20000715	KR 1999-702008	19990310
	BG 64214	B1	20040531	BG 1999-103250	19990315
	US 6344449	B1	20020205	US 1999-254281	19991012
	HK 1021192	A1	20040430	HK 1999-105722	19991208
	US 2001036946	A1	20011101	US 2001-789391	20010221
	US 2003069231	A1	20030410	US 2002-119875	20020410
	US 2004214819	A1	20041028	US 2004-835495	20040429
PRAI	DE 1996-19636623	A	19960910		
	DE 1997-19720011	A	19970514		
	WO 1997-EP4862	W	19970908		
	US 1999-254281	A1	19991012		
	US 2001-789391	A1	20010221		
	US 2002-119875	B1	20020410		

OS MARPAT 128:257695

GI



I



II

AB The invention concerns modified amino acids of general formula I [A = bond, CX; Z = CH2, NR1; R1 = H, alkyl, phenyl-alkyl; X = O, H,H; n = 1-2; m = 0-1; R = (substituted)alkyl; R2 = Ph, (substituted)(hetero)(bi)cycle; R3 = H, (substituted)alkyl, Ph, pyridinyl; R4 = H, (substituted)alkyl; R3R4= (hetero)cycle; R5 = H, alkyl, alkoxycarbonyl, PhCH2], pharmaceuticals containing these compds., their use and the method for their

production, as well as their use for the production and purification of antibodies and
as marked compds. in RIA and ELISA assays and as diagnostic or analytic auxiliary agents in neurotransmitter research. Thus, 3,5-dibromo-N2-[4-(1,3-dihydro-2(2H)-oxo-benzimidazol-1-yl)-1-piperidinyl]carbonyl-D-tyrosine was reacted with 1-(4-pyridinyl)-piperazine, to give II(22%). Title compds. show human calcitonin gene related peptide (CGRP) antagonist activity; in in-vitro binding studies with Sk-N-MC-cells, I had IC50 ≤10000 nM, and in the same system, had CGRP-antagonist activity at doses from 10-11 to 10-6 M.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs 27

L4 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:186625 CAPLUS
DN 128:230701
TI Preparation of varied amino acids as calcitonin gene-related peptide antagonists in pharmaceutical compositions
IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Pieper, Helmut; Doods, Henri; Hallermayer, Gerhard; Entzeroth, Michael; Wienen, Wolfgang
PA Karl Thomae G.m.b.H., Germany
SO Ger. Offen., 142 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19636623	A1	19980312	DE 1996-19636623	19960910
	CA 2262818	A1	19980319	CA 1997-2262818	19970908
	WO 9811128	A1	19980319	WO 1997-EP4862	19970908
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9741196	A	19980402	AU 1997-41196	19970908
	AU 721035	B2	20000622		
	EP 927192	A1	19990707	EP 1997-938928	19970908
	EP 927192	B1	20040512		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712023	A	19990831	BR 1997-12023	19970908
	CN 1230196	A	19990929	CN 1997-197772	19970908
	CN 1129605	B	20031203		
	JP 2000505100	T	20000425	JP 1998-513227	19970908
	JP 3483893	B2	20040106		
	JP 2003300959	A	20031021	JP 2003-21750	19970908
	AT 266673	T	20040515	AT 1997-938928	19970908
	EP 1440976	A1	20040728	EP 2004-3959	19970908
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	PT 927192	T	20040930	PT 1997-938928	19970908
	EE 4375	B1	20041015	EE 1999-115	19970908
	ES 2221691	T3	20050101	ES 1997-938928	19970908
	PL 190180	B1	20051130	PL 1997-331989	19970908

	ZA 9708083	A	19991217	ZA 1997-8083	19970909
	HR 970481	B1	20031031	HR 1997-481	19970909
	TW 477792	B	20020301	TW 1997-86113120	19970910
	TW 498076	B	20020811	TW 2000-89125839	19970910
	NO 9901130	A	19990505	NO 1999-1130	19990309
	BG 64214	B1	20040531	BG 1999-103250	19990315
	US 6344449	B1	20020205	US 1999-254281	19991012
	HK 1021192	A1	20040430	HK 1999-105722	19991208
PRAI	DE 1996-19636623	A	19960910		
	DE 1997-19720011	A	19970514		
	EP 1997-938928	A3	19970908		
	JP 1998-513227	A3	19970908		
	WO 1997-EP4862	W	19970908		

OS MARPAT 128:230701

GI



II

AB Title compds. RCOZCR1R2C(:X)ANR3R4 [(I); R = (substituted) alkyl; R1 = H, alkyl, PhCH2; R2 = (CO)m(CH2)nR5; m = 0, 1; n = 1, 2; R5 = Ph, heterocycle; X = O, (H,H); Z = CH2, NR6; R6 = H, alkyl, phenyl-alkyl; A = bond, proline; R3 = H, substituted alkyl, Ph, pyridinyl; R4 = H, substituted alkyl; NR3R4 = (substituted) heterocycle], useful as calcitonin gene-related peptide (CGRP) antagonists, were prepared Thus, 3,5-dibromo-N2-[4-(1,3-dihydro-2(2H)-oxo-benzimidazol-1-yl)-1-piperidinyl]carbonyl-D-tyrosine was reacted with 1-(4-pyridinyl)-piperazine, to give II (22%). In in-vitro binding studies with human CGRP-receptors, I had IC50 ≤10000 nM; in CGRP-antagonist in vitro tests, I was effective at doses from 10-11 to 10-5 M.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H44 Br2 F N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C33 H37 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-bromophenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]- (9CI)
MF C35 H45 Br N6 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H34 Br2 F N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-(9CI)
MF C37 H51 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H45 Br2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H33 Br2 F N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(4-cyano-4-phenyl-1-piperidinyl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C36 H37 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-[(dimethylamino)methyl]phenyl]- (9CI)
MF C38 H45 Cl2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-(4-cyclopentyl-1-piperazinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H40 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI)
MF C30 H32 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]- (9CI)
MF C35 H44 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-8-methoxy-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H38 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C33 H42 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H42 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, (R)- (9CI)
MF C34 H36 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxothieno[3,4-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C31 H35 Br2 N7 O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C35 H45 F3 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C33 H43 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[1'-(methylsulfonyl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H44 Br2 N6 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(2,5-dioxo-4-phenyl-1-imidazolidinyl)-, [1(R)]- (9CI)
MF C34 H43 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-(3-

thienyl)-1H-imidazol-1-yl]-, (R)- (9CI)
MF C33 H42 Br2 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(3-methoxyphenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]- (9CI)
MF C36 H49 N7 O4

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H42 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(3-ethenylphenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]- (9CI)
MF C36 H48 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2,2-dioxido-3H-2,1,3-

benzothiadiazin-3-yl)-, (R)- (9CI)
MF C32 H37 Br2 N7 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C36 H44 Br2 F3 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C38 H53 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(5,6-dichloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H32 Br2 Cl2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-

2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-[2,3-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-1H-benzimidazol-1-yl]-, (R)- (9CI)

MF C38 H44 Br2 N8 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-4-(2-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)

MF C35 H44 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C35 H42 Br2 F3 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[[3-[2-

(dimethylamino)ethoxy]phenyl]methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)

MF C38 H55 N7 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)

MF C30 H33 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(3-methylphenyl)methyl]-1,4-dioxobutyl]- (9CI)

MF C35 H47 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-[4-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]- (9CI)
MF C35 H44 Br2 Cl N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C36 H43 Br2 F3 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C36 H47 Br2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[3-(dimethylamino)propyl]-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H43 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C35 H46 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-

1-oxopropyl]-, 1,1-dimethylethyl ester, (R)- (9CI)
MF C38 H51 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C36 H45 Br2 F3 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromo-4-methoxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)- (9CI)
MF C35 H46 Br2 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H35 Br2 F N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H40 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C34 H44 F3 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)

MF C34 H43 Br2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H41 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C34 H43 Br2 N9 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C33 H35 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3-chlorophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H45 Cl N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H33 Cl2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI)
MF C30 H35 Br2 N5 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(dimethylamino)[1,4'-bipiperidin]-1'-yl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C35 H48 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-(1'-methyl[4,4'-bipiperidin]-1-yl)-1-[(3-nitrophenyl)methyl]-2-oxoethyl]-(9CI)
MF C34 H45 N7 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C30 H38 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C34 H35 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-[4-(4-amino-3,5-dibromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-

bipiperidin]-1'-yl-2-oxoethyl]-, (R)- (9CI)
MF C34 H42 Br4 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-(4-cyano-4-phenyl-1-piperidinyl)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C35 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE .'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-, 1,1-dimethylethyl ester (9CI)
MF C40 H52 F3 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C34 H42 Br2 F N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C30 H33 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-methylphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxothieno[3,4-d]pyrimidin-3(2H)-yl)- (9CI)
MF C32 H44 N6 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-(9CI)
MF C34 H42 Br2 N6 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3,4-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H45 Br2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C34 H42 Br2 F N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-pyrazinyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C30 H32 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-carboxylic acid, 1'-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester, (R)-

(9CI)
MF C38 H50 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI)
MF C33 H34 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[(4-methoxy-3,5-dimethylphenyl)methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C37 H52 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C35 H43 Br2 N5 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H34 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H36 Br2 F N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(2,3-dihydro-6-hydroxy-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C32 H41 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-methoxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-, (R)- (9CI)

MF C30 H33 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxamide, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, (R)- (9CI)
MF C34 H38 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinylcarbonyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H36 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-[2,3-dihydro-4-(4-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H39 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C36 H44 F6 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H36 Br2 N6 O4

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxamide, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-N-(2-hydroxyethyl)-2-oxo-, (R)- (9CI)
MF C36 H48 Br2 N8 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H45 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxothieno[3,2-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C31 H40 Br2 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-chlorophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI)
MF C33 H43 Cl N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H43 Br2 N7 O3

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-butanoic acid, 1'-[3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-γ-oxo-, (R)- (9CI)
MF C37 H47 Br2 N7 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—CO_2H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,5-dioxo-4-phenyl-1-imidazolidinyl)-, [1(R)]- (9CI)
MF C34 H36 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C35 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-(1-ethyl-4-piperidinyl)-1-piperazinyl]-1-[(3-methoxyphenyl)methyl]-2-oxoethyl]- (9CI)
MF C35 H49 N7 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(2-propenyl)phenyl]methyl]butyl]- (9CI)
MF C37 H49 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,4-dichlorophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C33 H42 Cl2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C35 H42 Br2 F3 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[[3-(1-methylethoxy)phenyl]methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C37 H52 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Benzimidazole-1-acetic acid, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo-, methyl ester, (R)- (9CI)
MF C34 H38 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-acetic acid, 1'-[3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-, (R)- (9CI)
MF C35 H45 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS · REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-[2,3-dihydro-4-(2-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H45 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C35 H43 Br2 F3 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H45 Cl2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2-oxo-3(2H)-benzoxazolyl)-,

(R)- (9CI)
MF C32 H33 Br2 N5 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[4-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-1,4-dioxo-3-[[3-(trifluoromethyl)phenyl]methyl]butyl]- (9CI)
MF C36 H46 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-c]quinolin-3-yl)-, (R)- (9CI)
MF C35 H42 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-ethyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C35 H47 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[[3,4-difluoro-5-(trifluoromethyl)phenyl]methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)

MF C36 H44 F5 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H36 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C37 H45 Br2 F3 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxopyrido[3,4-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C32 H41 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(6-bromo-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H42 Br3 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C30 H34 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H36 Br2 F N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[4-(4-acetyl-1-piperazinyl)-1-piperidinyl]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H44 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (R)- (9CI)
MF C33 H41 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-

quinazolinyl)- (9CI)
MF C34 H43 F3 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)- (9CI)
MF C34 H37 Br2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C32 H34 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinylcarbonyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H35 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]- (9CI)
MF C37 H47 F3 N6 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C36 H46 F3 N7 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C29 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(dimethylamino)[1,4'-bipiperidin]-1'-yl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C36 H48 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C33 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(4-amino-3,5-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H46 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C32 H41 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1,2-dihydro-2-oxo-3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C33 H34 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-[4-(4-amino-3,5-dibromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-, (R)- (9CI)
MF C34 H43 Br4 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C31 H35 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxothieno[3,4-d]pyrimidin-3(2H)-yl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-1'-methyl- (9CI)
MF C34 H44 F3 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C34 H41 Br2 F N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H33 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-methylphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]- (9CI)
MF C36 H48 N6 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-(1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H34 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,4-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-(9CI)
MF C34 H44 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-methyl-, (R)- (9CI)
MF C34 H38 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(2-methoxyphenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C33 H36 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI)
MF C33 H39 N7 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-, [3(R)]- (9CI)
MF C33 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(4-methoxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C38 H53 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)- (9CI)
MF C35 H37 Br2 N5 O4

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H34 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-[(1-methyl-4-piperidinyl)carbonyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-6,7-dimethoxy-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C35 H40 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)

MF C34 H35 F6 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, (R)- (9CI)
MF C34 H37 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H43 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-[2,3-dihydro-4-(4-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C34 H38 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C35 H43 F6 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Benzimidazole-5-carboxylic acid, 1-[1-[[[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo-, methyl ester, (R)- (9CI)
MF C34 H36 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-(1'-acetyl[4,4'-bipiperidin]-1-yl)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C35 H45 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-

(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C35 H45 Br2 N7 O4

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,2-dihydro-2-oxothieno[3,4-d]pyrimidin-3(4H)-yl)- (9CI)
MF C31 H40 Br2 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-1'-methyl- (9CI)
MF C36 H46 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(3,4-dihydro-2-oxo-1(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H42 Br2 N6 O4

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-hexyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C39 H55 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-[2,5-dioxo-4-(phenylmethyl)-1-imidazolidinyl]-, [1(R)]- (9CI)
MF C35 H39 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(3-methoxyphenyl)methyl]-1,4-dioxobutyl]- (9CI)
MF C35 H47 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H43 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[(3-propylphenyl)methyl]butyl]- (9CI)
MF C37 H51 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(4-[1,1'-biphenyl]-4-yl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-,.(R)- (9CI)
MF C40 H47 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C35 H41 Br2 F3 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[3-(1-methylethoxy)phenyl]methyl]-1,4-dioxobutyl]- (9CI)
MF C37 H51 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-, (R)- (9CI)
MF C31 H35 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-acetic acid, 1'-[(2R)-3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C35 H44 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,4-dichlorophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI)
MF C32 H35 Cl2 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,2-dihydro-2-oxothieno[3,4-d]pyrimidin-3(4H)-yl)- (9CI)
MF C31 H41 Br2 N7 O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)- (9CI)
MF C34 H44 Cl2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C30 H32 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxamide, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-N-(2-hydroxyethyl)-2-oxo-, (R)- (9CI)
MF C36 H42 Br2 N8 O5

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, methyl ester, (R)- (9CI)
MF C35 H39 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-ethyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C36 H47 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[[3,4-difluoro-5-(trifluoromethyl)phenyl]methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)- (9CI)
MF C35 H43 F5 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)- (9CI)
MF C32 H41 Br2 N7 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[4-(3-bromophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]- (9CI)
MF C36 H45 Br3 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxopyrido[3,4-

d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C33 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,3-dihydro-5-methyl-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C36 H47 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4,4'-Bipiperidine, 1-[2-[(3,5-dibromo-4-methoxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C36 H47 Br2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C34 H36 Br2 F N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)

MF C31 H34 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[4-(4-acetyl-1-piperazinyl)-1-piperidinyl]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-

(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)-, (R)- (9CI)
MF C33 H42 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C33 H36 F3 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[4-(1-cyclohexyl-4-piperidinyl)-1-piperazinyl]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C38 H51 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxylic acid, 4-[4-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-1-piperazinyl]-, 1,1-dimethylethyl ester, (R)- (9CI)
MF C36 H47 Br2 N7 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[4-[4-(dimethylamino)butyl]phenyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C39 H50 Br2 N8 O3

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NMe_2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(3-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]- (9CI)
MF C35 H44 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-morpholinyl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H40 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H41 Br N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI)
MF C34 H43 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-[[(phenylamino)carbonyl]amino]-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C35 H39 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[2-(trifluoromethyl)phenyl]methyl]butyl]-1'-methyl- (9CI)
MF C36 H46 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C33 H43 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,6,7,8-tetrahydro-6,8-dioxo-9H-purin-9-yl)-, (R)- (9CI)
MF C30 H38 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-bromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H43 Br N6 O3





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C32 H34 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3-bromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H46 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C33 H34 Br2 F N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-pyrazinyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C30 H33 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-methylphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C36 H45 F3 N6 O3





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI)
MF C33 H35 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(4-hydroxy-3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]-(9CI)
MF C36 H49 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)-(9CI)
MF C33 H36 Br2 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H35 Br2 N9 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]- (9CI)
MF C34 H40 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-2-[4-(4-acetylphenyl)-1-piperazinyl]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C36 H39 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[2-[(3,5-dibromo-4-methylphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-[4-[4-(dimethylamino)butyl]phenyl]- (9CI)
MF C41 H52 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-azepin-1-yl)- (9CI)
MF C36 H45 Br2 N5 O4

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C32 H37 Br2 N9 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C32 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(5-chloro-1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-, (R)- (9CI)
MF C33 H35 Br2 Cl N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)

MF C35 H42 F6 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-, (R)- (9CI)
MF C33 H40 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo- (9CI)
MF C34 H43 Br2 N7 O5
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H46 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-4-(4-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C36 H47 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3-bromophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H45 Br N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C34 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-benzoyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C40 H47 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)

MF C34 H44 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-

methoxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-
(9CI)
MF C34 H46 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-
2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(7,8-dihydro-8-oxo-9H-purin-9-
yl)-, (R)- (9CI)
MF C30 H32 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-
[1'-(cyclopropylmethyl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-4-(1,4-dihydro-
2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C37 H49 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[2,5-dioxo-4-(phenylmethyl)-1-imidazolidinyl]-, [1(R)]- (9CI)
MF C35 H44 Br2 N6 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C35 H45 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[(3-ethoxyphenyl)methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C36 H50 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C33 H36 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[3-(3,5-dibromo-4-hydroxyphenyl)-2-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-, (R)- (9CI)
MF C28 H31 Br2 N5 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-[2,3-dihydro-4-(2-naphthalenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C38 H45 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-(3-thienyl)-1H-imidazol-1-yl]- (9CI)
MF C32 H40 Br2 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(3,5-dimethylphenyl)methyl]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H33 Br2 F N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidineacetic acid, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C31 H36 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-[4-(3,4-dichlorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H43 Br2 Cl2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxothieno[3,2-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C31 H42 Br2 N8 O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-methyl-1-piperazinyl)-(9CI)
MF C34 H44 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(2,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9CI)
MF C32 H34 Br2 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-[1,4-dihydro-7-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3(2H)-quinazolinyl]-, (R)- (9CI)
MF C39 H47 Br2 N9 O4

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-ethyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C37 H46 Br2 F3 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinecarboxylic acid, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-, ethyl ester (9CI)
MF C32 H38 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI)
MF C31 H34 Br2 N8 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1-piperazinyl]-2-oxoethyl]-4-[2,3-dihydro-4-(3-methoxyphenyl)-2-oxo-1H-imidazol-1-yl]-(9CI)
MF C37 H48 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-

(4-methyl-1-piperazinyl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxopyrido[3,4-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)

MF C32 H42 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-4-(3-nitrophenyl)-2-oxo-1H-imidazol-1-yl]- (9CI)

MF C35 H44 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C35 H44 F4 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI)
MF C32 H34 Br2 N6 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-(4'-acetyl[1,1'-bipiperazin]-4-yl)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C34 H43 Br2 N9 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4,5-diphenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C41 H49 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C34 H37 F3 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[2-[1'-

(1-methylethyl)[4,4'-bipiperidin]-1-yl]-2-oxo-1-[[3-(trifluoromethyl)phenyl]methyl]ethyl]- (9CI)
MF C37 H49 F3 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3-bromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C32 H35 Br N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[4-[4-(dimethylamino)butyl]phenyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C40 H50 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)-, (R)- (9CI)
MF C31 H33 Br2 N7 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[3-(trifluoromethyl)phenyl]methyl]butyl]-4-(1-methyl-4-piperidinyl)- (9CI)
MF C35 H45 F3 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(dimethylamino)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C30 H39 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H38 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(dimethylamino)[1,4'-bipiperidin]-1'-yl]-2-oxoethyl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)-, (R)- (9CI)
MF C36 H47 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,4'-Bipiperidine]-1'-carboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C37 H46 Br2 N10 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C37 H45 F6 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, methyl ester, (R)- (9CI)
MF C35 H45 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-

cyanophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-
(9CI)
MF C34 H43 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-
2-[4-(4-pyrimidinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-
quinazolinyl)-, (R)- (9CI)
MF C31 H34 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[2-[(3-bromophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-
3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H44 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[4-(4-fluorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H43 Br2 F N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C30 H32 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3-bromophenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-1-yl]- (9CI)
MF C35 H42 Br F3 N6 O3





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)-, [3(R)]- (9CI)
MF C33 H37 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[(4-hydroxy-3,5-dimethylphenyl)methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C36 H50 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperazine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-1-piperidinyl]-1,4-dioxobutyl]-4-(4-pyridinyl)- (9CI)
MF C34 H36 Br2 N6 O4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H34 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(4-hydroxy-3,5-dimethylphenyl)methyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C34 H46 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[4-(4-acetylphenyl)-1-piperazinyl]-1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C35 H39 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[4-(1,1-dimethylethyl)phenyl]methyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C39 H55 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Piperidine, 1-[2-[(3,5-dibromo-4-hydroxyphenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-4-(hexahydro-1H-azepin-1-yl)- (9CI)
MF C35 H45 Br2 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C32 H34 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4,4'-bipiperidin]-1-yl-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C33 H43 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C33 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C33 H35 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(hexahydro-1H-azepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)

MF C36 H44 F6 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C33 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, (R)- (9CI)
MF C34 H42 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1-piperidinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C35 H46 Br2 N8 O3

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(1,4-dihydro-2-oxothieno[3,4-d]pyrimidin-3(2H)-yl)-, (R)- (9CI)
MF C31 H34 Br2 N6 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3-bromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI)
MF C34 H45 Br N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)
MF C34 H36 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1'-(methylsulfonyl)[4,4'-bipiperidin]-1-yl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
MF C34 H45 Br2 N7 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5. 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxylic acid, 3-[1-[[[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-2-oxo-, methyl ester; (R)- (9CI)
MF C35 H38 Br2 N6 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)

MF C35 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[1-[(3-methoxyphenyl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- (9CI)
MF C34 H47 N7 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, (R)- (9CI)
MF C34 H45 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [4,4'-Bipiperidine]-1-acetic acid, 1'-[3-(4-amino-3,5-dibromophenyl)-2-[[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]carbonyl]amino]-1-oxopropyl]-, ethyl ester, (R)- (9CI)
MF C37 H49 Br2 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,4-dihydro-2,2-dioxido-3H-2,1,3-benzothiadiazin-3-yl)- (9CI)
MF C32 H43 Br2 N7 O4 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (9CI)
MF C34 H44 Br2 N8 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4'-Bipiperidine, 1'-[4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[(3-ethoxyphenyl)methyl]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-(2,3-dihydro-2-oxo-4-phenyl-1H-imidazol-1-yl)- (9CI)
MF C35 H45 Br2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-piperidinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)
MF C31 H39 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[2-[1,4'-bipiperidin]-1'-yl-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-[2,3-dihydro-4-(2-naphthalenyl)-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C38 H44 Br2 N6 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-

[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,5-dihydro-5-oxo-3-phenyl-1H-1,2,4-triazol-1-yl)- (9CI)

MF C33 H43 Br2 N9 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Piperidine, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-[3-[(3,5-dimethylphenyl)methyl]-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)

MF C36 H50 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)

MF C32 H34 Br2 F N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidineacetic acid, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-, ethyl ester (9CI)
MF C33 H40 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[4-(3,4-dichlorophenyl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H43 Br2 Cl2 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-(1,4-dihydro-2-oxothieno[3,2-d]pyrimidin-3(2H)-yl)- (9CI)
MF C31 H41 Br2 N7 O3 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4,4'-Bipiperidine, 1-[2-[(3,5-dibromophenyl)methyl]-4-[4-(1,4-dihydro-2-

oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-1'-methyl- (9CI)
MF C35 H45 Br2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(2,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C31 H33 Br2 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Quinazolinecarboxamide, 3-[1-[[[1-[(4-amino-3,5-dibromophenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperidinyl]ethyl]amino]carbonyl]-4-piperidinyl]-1,2,3,4-tetrahydro-N-methyl-2-oxo-, (R)- (9CI)
MF C35 H40 Br2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[(1R)-1-[(4-amino-3,5-dibromophenyl)methyl]-2-(1'-methyl[4,4'-bipiperidin]-1-yl)-2-oxoethyl]-4-[2,3-dihydro-4-(3-hydroxyphenyl)-2-oxo-1H-imidazol-1-yl]- (9CI)
MF C35 H45 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(4-amino-3,5-dibromophenyl)methyl]-2-[1,4'-bipiperidin]-1'-yl-2-oxoethyl]-4-[2,3-dihydro-2-oxo-4-[4-

(trifluoromethyl)phenyl]-1H-imidazol-1-yl]-, (R)- (9CI)
MF C35 H42 Br2 F3 N7 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidineacetic acid, 1-[2-[(3,4-dichlorophenyl)methyl]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-, methyl ester (9CI)
MF C32 H38 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-[4-

(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-2-oxoethyl]-4-(2,3-dihydro-2-oxo-5-phenyl-1H-imidazol-1-yl)-, (R)- (9CI)

MF C33 H36 Br2 N8 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 421 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Piperidinecarboxamide, N-[1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-, (R)- (9CI)

MF C31 H33 Br2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT